We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current LCTX market cap is 173.73M. The company's latest EPS is USD -0.1138 and P/E is -8.00.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 3.23M | 1.25M | 2.09M | 1.44M | 1.41M |
| Operating Income | -5.02M | -6.71M | -6.36M | -6.66M | -5.87M |
| Net Income | -5.23M | -7.11M | -4.78M | -6.54M | -5.76M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 3.52M | 1.83M | 4.34M | 14.7M | 8.95M |
| Operating Income | -38.88M | -26.45M | -49.21M | -22.52M | -24.73M |
| Net Income | -11.71M | -20.65M | -43.02M | -26.27M | -21.49M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 111.69M | 106.15M | 101.02M | 108.48M | 102.8M |
| Total Liabilities | 40.43M | 39.49M | 39M | 37.49M | 35.93M |
| Total Equity | 71.26M | 66.66M | 62.02M | 70.99M | 66.88M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 125.48M | 107.95M | 174.55M | 123.66M | 101.02M |
| Total Liabilities | 14.23M | 12.82M | 83.65M | 51.73M | 39M |
| Total Equity | 111.25M | 95.13M | 90.9M | 71.94M | 62.02M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -17.51M | -22.55M | -28.57M | -5.78M | -10.96M |
| Investing | 34.59M | 36.71M | 46.45M | -38k | -8.83M |
| Financing | 5.63M | 6.44M | 6.42M | 14.02M | 14.13M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -31.95M | -19.75M | -23.56M | 1.06M | -28.57M |
| Investing | 16.96M | 13.04M | 9.75M | -46.16M | 46.45M |
| Financing | 617k | 29.87M | 36.93M | 1.63M | 6.42M |
| Market Cap | 173.73M |
| Price to Earnings Ratio | -8.00 |
| Price to Sales Ratio | 19.2 |
| Price to Cash Ratio | 4.85 |
| Price to Book Ratio | 2.77 |
| Dividend Yield | - |
| Shares Outstanding | 188.84M |
| Average Volume (1 week) | 513.85k |
| Average Volume (1 Month) | 427.39k |
| 52 Week Change | -5.15% |
| 52 Week High | 1.61 |
| 52 Week Low | 0.7665 |
| Spread (Intraday) | 0.05 (5.4%) |
| Company Name | Lineage Cell Therapeutics Inc |
| Address |
2173 salk avenue alameda, california 92008 |
| Website | https://lineagecell.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
